Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/INCY
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Incyte Corporation (INCY) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Read full analysis

Key Stats

  • Market Cap
    $23.11B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $118.52
  • 52W Low
    $67.38
  • Typical Hold Time
    -
  • Enterprise Value
    $19.13B
  • Div Yield
    -
  • Trading Activity
    -
$117.7
52W Low: $67.38
21 Jul 2025
52W High: $118.52
09 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $67.38 and a high of $118.52, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Most Recent News

Content is generated by Aura AI

Global operating costs surge in Q2 amid Middle East conflict, but economic confidence shows slight recovery.

The Q2 2026 Global Economic Conditions Survey by ACCA and IMA reveals a sharp rise in operating costs for accountants and CFOs worldwide, driven by the Middle East conflict, soaring commodity prices, and supply chain issues. Over 75% of accountants a...

Market News
47 minutes ago
Acca And Ima
Bearish
news icon
pluang ai news

Zoom appoints Carlos Quaderi as Head of APAC to lead AI-driven growth phase

Zoom Video Communications has appointed Carlos Quaderi as Head of Asia Pacific (APAC), effective August 1, 2026. Quaderi will oversee Zoom's go-to-market strategy across APAC, including Australia, New Zealand, Asia, India, and Korea (excluding Japan)...

Market News
2 hours ago
Hayley Yap
Bullish
news icon
pluang ai news

Anthropic to pay $1.5B in largest US AI copyright settlement over training data use

Anthropic will pay a historic $1.5 billion settlement for copyright violations related to using authors' works to train its Claude AI chatbot. The U.S. District Judge approved the settlement, marking the largest copyright award in U.S. history. This ...

Market News
4 hours ago
PYMNTS
Neutral
pluang ai news
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $23.11B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $118.52
  • 52W Low
    $67.38
  • Typical Hold Time
    -
  • Enterprise Value
    $19.13B
  • Div Yield
    -
  • Trading Activity
    -
$117.7
52W Low: $67.38
21 Jul 2025
52W High: $118.52
09 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $67.38 and a high of $118.52, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!